Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 932414 | ISIN: CA58501R1029 | Ticker-Symbol: 47M
Frankfurt
15.05.25 | 18:57
0,049 Euro
+5,38 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDMIRA INC Chart 1 Jahr
5-Tage-Chart
MEDMIRA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0430,05620:46
0,0410,05920:40
ACCESS Newswire
235 Leser
Artikel bewerten:
(1)

MedMira, Inc.: MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal G4 HIV-1/2 rapid test for VA, Department of Defense

Finanznachrichten News

HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems.

The Reveal® G4 HIV-1/2 antibody rapid test (Reveal® G4 HIV) is the world's fastest HIV rapid test. Based on MedMira's patented Rapid Vertical Flow Technology, the Reveal® G4 HIV offers a simple testing solution with immediate results which do not fade away. Therefore, offering the best rapid testing solution which is FDA approved since 2004. The Reveal® G4 HIV is offered in three convenient formats (Point-of-Care finger-stick whole blood, Laboratory format Serum/Plasma and venipuncture whole blood) to accommodate any health care setting without the need for timing devices. With its unique built-in procedural and reagent control line, an operator can be assured that each test has been performed correctly.

A unique feature of MedMira's patented technology is the elimination of the prozone (hook) effect, a known common issue in traditional serological tests, where a high concentration of antibodies can lead to false-negative results. MedMira's technology avoids this by ensuring antibody binding occurs in a controlled, localized environment, while excess antibodies are washed away. The result is a highly accurate test that maintains reliability across a wide range of antibody levels.

As MedMira's SDVOSB Vendor, Lovell is excited to bring this product to federal healthcare providers. MedMira is now available through the Department of Veterans Affairs' Federal Supply Schedule (FSS), GSA Advantage, the Defense Logistics Agency's Electronic Catalog (ECAT), and the Department of Defense's Distribution and Pricing Agreement (DAPA). Listing products on contract vehicles with Lovell streamlines the acquisition process while helping government agencies meet their SDVOSB procurement goals.

"We're proud to partner with MedMira to bring an advanced rapid testing solution to federal healthcare providers. The speed and reliability of their Reveal® G4 platform supports clinicians in making timely decisions and improves the care experience for our veterans," said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.

"MedMira is proud to partner with Lovell Government Services, SDVOSB, to support Federal procurement needs through their eCAT, GSA, and VA FSS contract vehicles," said Nicole Crenshaw, VP of Commercial Operations at MedMira. "This strategic partnership provides us with the critical reach into key government markets, enabling greater access to our innovative diagnostic solutions where they're needed most."

About MedMira

MedMira is the developer and owner of Rapid Vertical Flow (RVF)® Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal®, Multiplo® and Miriad® brands in global markets. MedMira's HIV rapid test has been the first approved in Canada and the second HIV rapid test approved in the United States.

For more information visit medmira.com. Follow us on Twitter and LinkedIn.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For Media Inquiries:
Markus Meile
ir@medmira.com
902-450-1588

About Lovell Government Services

Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market. Lovell is a three-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.

Learn more at www.lovellgov.com

For Media Inquiries:
Jeff McKay
media@lovellgov.com
850-912-4680

SOURCE: MedMira, Inc.



© 2025 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.